Janux Therapeutics (JANX) vs Kura Oncology (KURA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Kura Oncology (KURA) has outperformed Janux Therapeutics (JANX) over the past year, losing 38.1% versus a loss of 65.0%. Over five years, JANX leads with a -42.9% price change compared with -50.7% for KURA. Kura Oncology is the larger company by market cap ($634.9 million vs $616.7 million), about 1.0 times the size.
Kura Oncology converts more of its revenue into profit, with a net margin of -412.9% versus -1136.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | JANX | KURA |
|---|---|---|
| Share price | $10.08 | $6.91 |
| Market cap | $616.73M | $634.88M |
| 1-day change | -2.04% | -5.99% |
| YTD return | -26.96% | -33.49% |
| 1-year return | -65.00% | -38.14% |
| 5-year return | -42.92% | -50.66% |
| EPS (TTM) | $-1.59 | $-3.30 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $10.00M | $67.48M |
| Revenue growth (YoY) | -5.55% | +25.24% |
| Net income (latest FY) | $-113.63M | $-278.67M |
| Operating margin | -1576.67% | -449.94% |
| Net margin | -1136.25% | -412.95% |
| 52-week high | $35.34 | $13.90 |
| 52-week low | $10.05 | $6.75 |
| Distance from 52-week high | -71.48% | -50.29% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +228.77% | +357.60% |
| Average volume | 961.56K | 2.10M |
| Shares outstanding | 61.18M | 91.88M |
| Employees | 114 | 260 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KURA has outperformed JANX by 26.9 percentage points over the past year.
- Kura Oncology is more profitable, keeping -412.9 cents of every revenue dollar as net income versus -1136.3 cents for Janux Therapeutics.
- Kura Oncology grew revenue faster in its latest fiscal year (+25.24% vs -5.55%).
About Janux Therapeutics
JANX stock →Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 114 employees
About Kura Oncology
KURA stock →Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 260 employees
JANX vs KURA FAQ
Which is bigger, Janux Therapeutics or Kura Oncology?
Kura Oncology (KURA) is larger, with a market capitalization of $634.88M compared with $616.73M for Janux Therapeutics (JANX).
Which stock has performed better over the past year, JANX or KURA?
KURA returned -38.14% over the past 12 months, compared with -65.00% for JANX (price return, excluding dividends). Past performance does not predict future results.
Are Janux Therapeutics and Kura Oncology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.